Reuters
2022.08.03 00:09

AC Immune To Present Data From Phase II Crenezumab Alzheimer’s Prevention Initiative Study

Aug 2 (Reuters) - AC Immune SA (ACIU.O) : * DETAILED DATA FROM THE PHASE II CRENEZUMAB ALZHEIMER’S PREVENTION INITIATIVE STUDY IN AUTOSOMAL DOMINANT ALZHEIMER’S DISEASE PRESENTED AT AAIC * AC IMMUNE SA - CRENEZUMAB WAS SAFE AND WELL TOLERATED WITH NO CASES OF ARIA-E OBSERVED DURING UP TO EIGHT-YEAR STUDY
The copyright of this article belongs to the original author/organization.
The current content only represents the author’s point of view, and has nothing to do with the position of Longbridge. The content is for investment reference only and does not constitute any investment advice. If you have any questions or suggestions about the content services provided by Longbridge, please contact: editorial@longbridge.global

Like